ENGN: enGene Holdings Inc. Growth-Adjusted Market Cap to Net Income

Brandmark of enGene Holdings Inc. (ENGN)

The lack of profitable assets forces enGene Holdings Inc. (ENGN) to rely on external investments to cover expenses. The ratio of the company's valuation to its growth rate reflects the dynamics of this process, where the 0.00 level represents the current value. The development of non-viral bladder cancer therapies reduces clinic costs, yet clinical trial uncertainty and competition create significant risks to business sustainability.

ENGN enGene Bio: Price/Earnings to Growth Ratio in the range 02/21/2024 - 11/18/2026

Metric breakdowns and analytics for enGene Bio (ENGN)

- share price and consensus valuation forecast:
- market capitalization information:
General company analysis:ENGN - enGene Bio
Signature product of enGene Holdings Inc

Investors use this ratio to determine the fair value of an asset by comparing the P/E market multiple to the rate of earnings expansion. Given the complexities of scaling production and strict FDA oversight regarding the safety of enGene Holdings Inc. (ENGN) therapies, the history of P/E to growth rates helps determine whether the potential upside offsets current engineering risks, classifying the asset as either undervalued or overpriced.

Competing companies

ARGX (Argenx) - Growth-Adjusted Payback Ratio|PEG Multiple BNTX (biontech.de)|Growth-Adjusted Market Cap to Net Income Abivax S.A. (ABVX)|ADMA - Price/Earnings to Growth Ratio|Protagonist Therapeutics, Inc. (PTGX) - Price/Earnings to Growth Multiple|Immunovant Therapeutics (IMVT) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Kiniksa Pharmaceuticals|Price/Earnings to Growth Multiple GRFS|PEG Multiple adaptivebiotech.com|Price/Earnings to Growth Ratio Celldex (CLDX)|Aurinia Pharmaceuticals Inc. - Growth-Adjusted P/E Ratio|PEG Multiple BCRX (biocryst.com)|Vera Therapeutics, Inc. (VERA) - Price to Earnings Adjusted for Growth Rate|Dianthus Therapeutics, Inc. - PEG Multiple|Market Cap to Earnings and Growth Ratio PHVS|ABCL: PEG Multiple|Price to Earnings Adjusted for Growth Rate Tourmaline Corp (TRML)|PGEN (precigen.com) - PEG Multiple|PEG Multiple Pharming Corp|Price/Earnings to Growth Multiple NKTR (Nektar)|UPB (Upstream Bio Inc) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Zenas Bio ZBIO|IMNM: Growth-Adjusted P/E Ratio|GOSS - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income KalVista Pharmaceuticals KALV|Septerna (SEPN) - Price/Earnings to Growth Ratio|pieris.com - Growth-Adjusted Payback Ratio|SVRA (Savara Inc) - PEG Multiple|RIGL: Growth-Adjusted Payback Ratio|PEG Multiple ANAB|ATXS (Astria Pharma) - Growth-Adjusted Payback Ratio|PEG Multiple RAPT (rapt.com)|Company Value to Earnings Growth Ratio JBIO (Aerovate)|Aclaris Therapeutics, Inc - PEG Multiple|Price to Earnings Adjusted for Growth Rate Kyverna Therapeutics Inc.|TLSA: PEG Multiple|CABA - Growth-Adjusted Market Cap to Net Income|VTYX (ventyxbio.com) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Theratechnologies Inc. THTX|Price/Earnings to Growth Multiple AVTX (avalotx.com)|Price/Earnings to Growth Multiple Eledon Pharmaceuticals, Inc. ELDN|Price/Earnings to Growth Ratio Agenus, Inc AGEN|Climb Bio Inc - Price/Earnings to Growth Ratio|Zura Bio Limited - PEG Multiple|Growth-Adjusted Market Cap to Net Income aTyr Pharma, Inc. ATYR|ADAG: PEG Multiple|Market Cap to Earnings and Growth Ratio IMA (ImageneBio)|Price/Earnings to Growth Multiple STTK|EQ: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Connect Pharma (CNTB)|PEG Multiple Immunic Therapeutics (IMUX)|PEG Multiple ATRA (Atara Biotherapeutics)|Growth-Adjusted Payback Ratio IFRX|XFOR (X4 Pharma) - Price to Earnings Adjusted for Growth Rate|Growth-Adjusted Payback Ratio ACET (adicetbio.com)|CELU: PEG Multiple|inmunebio.com (INMB) - PEG Multiple|BRNS (Barinthus Biotherapeutics PLC) - PEG Multiple|KZR: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio SAB Biotherapeutics, Inc. (SABS)|AKTX (Akari Therapeutics plc) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Enlivex Therapeutics Ltd ENLV|QTTB - Price/Earnings to Growth Multiple|geovax.com - PEG Multiple|Growth-Adjusted Payback Ratio EDSA (Edesa Biotech Inc)|IBIO: PEG Multiple|Carisma Tx (CARM) - PEG Multiple|XTLB (XTL Biopharmaceuticals) - PEG Multiple|BOLT: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Multiple HCWB (HCW Biologics, Inc.)|PEG Multiple Aptevo (APVO)|PEG Multiple AIM (aimimmuno.com)|PEG Multiple Aditxt Corp ADTX|GRI: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio XRTX (xortx.com)|Vyome Holdings Inc. (HIND) - Price/Earnings to Growth Ratio|Revelation Bio (REVB) - PEG Multiple|INDP (Indaptus Corp) - PEG Multiple|SCNI: Growth-Adjusted Payback Ratio|PEG Multiple CALI|Price/Earnings to Growth Multiple Affimed N.V. AFMD|Price/Earnings to Growth Ratio Allakos ALLK|HOOK: Growth-Adjusted P/E Ratio|IGMS - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income iTeos Therapeutics ITOS|Ocean Biomedical (OCEA) - Price/Earnings to Growth Ratio|tcbiopharm.com (TCBP) - PEG Multiple|THRD (Third Harmonic Bio Inc.) - PEG Multiple